Advancing Diversity in Clinical Trials

Advancing Diversity in Clinical Trials

Published: May 20, 2024

Saumya Chatrath

Jungyeon Kim

Estrella Ndrianasy

Vanessa Baxley

Key Findings
  • Addressing the diversity gap in clinical trials is essential for advancing equitable healthcare and building trust in medical research.
  • Although there is evidence that the representation of women and Hispanic or Latino populations is slowly improving in clinical trials, there is still much work to be done.
  • By leveraging rich sources of RWD like Medicaid claims we can enhance inclusivity, improve the generalizability of trial findings, and ultimately advance healthcare for all.

Clinical trials are essential for assessing the safety and efficacy of a drug, biological product, or medical device and enabling benefit-risk calculations that inform approval by the Food and Drug Administration (FDA). Clinical trials also provide access to novel and potentially life-saving treatments for patients who have exhausted all other avenues. Despite their importance, the populations that participate in clinical trials have historically been significantly less diverse than the national population. In this whitepaper, we discuss the role that Medicaid claims can play as a real-world data source to improve the recruitment of underrepresented groups into clinical trials.

How do you apply evidence?

Take our quick four-question survey to help us curate evidence and insights that serve you.

Take our survey